FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286295684> ?p ?o ?g. }

• W4286295684 endingPage "TPS9593" @default.
• W4286295684 startingPage "TPS9593" @default.
• W4286295684 abstract "TPS9593 Background: RP1 is an oncolytic virus (HSV-1) that expresses a fusogenic glycoprotein (GALV-GP R-) and granulocyte macrophage colony stimulating factor (GM-CSF). In preclinical studies, RP1 induced immunogenic tumor cell death and provided potent systemic anti-tumor activity, which is further improved by combining anti-PD-1 therapy. The prognosis for advanced and metastatic cutaneous squamous cell carcinoma (CSCC) remains poor for many patients despite the adoption of cemiplimab and pembrolizumab as a standard treatment. Preliminary results from IGNYTE, a phase I/II clinical study of RP1 in combination with nivolumab showed a high rate of deep and durable responses in patients (pts) with CSCC. This study is evaluating the efficacy and safety of cemiplimab ± RP1 versus cemiplimab alone in advanced CSCC. Methods: This global, multicenter, randomized phase 2 study is enrolling pts with metastatic or unresectable, locally advanced CSCC who are not candidates for/refuse surgery and/or radiation therapy. Key eligibility criteria include no prior treatment with anti-PD1/PD-L1 antibodies or oncolytic viruses. The clinical trial is enrolling approximately 180 pts from centers in the EU, Australia, Canada, and USA. Pts are randomized in a 2:1 ratio to receive combination therapy or monotherapy respectively. Pts receive 350 mg of cemiplimab intravenously (IV) Q3W for up to 108 weeks. In the RP1 + cemiplimab arm, RP1 is injected intratumorally at a starting RP1 dose of 1 × 10 6 plaque-forming units (PFU)/mL alone, followed by up to 7 doses of RP1 at 1 × 10 7 PFU/mL Q3W together with the same dose of cemiplimab. Pts in the combination arm may receive up to 8 additional RP1 doses if protocol specific criteria are met. No crossover is allowed. Pts are stratified by disease status (nodal or distant metastatic or locally advanced CSCC) and prior systemic therapy. Tumor assessments are performed every 9 weeks. The dual independent primary endpoints are overall response rate and complete response rate, both by a blinded independent review. Secondary endpoints include safety, progression-free survival, duration of response, and overall survival. Exploratory endpoints include quality of life, and immune biomarker analyses. This trial is currently enrolling pts. Clinical trial information: NCT04050436." @default.
• W4286295684 created "2022-07-21" @default.
• W4286295684 creator A5001015275 @default.
• W4286295684 creator A5007005578 @default.
• W4286295684 creator A5012911914 @default.
• W4286295684 creator A5022491020 @default.
• W4286295684 creator A5025478490 @default.
• W4286295684 creator A5026878751 @default.
• W4286295684 creator A5029783882 @default.
• W4286295684 creator A5034414974 @default.
• W4286295684 creator A5037624715 @default.
• W4286295684 creator A5041474007 @default.
• W4286295684 creator A5056132643 @default.
• W4286295684 creator A5058902095 @default.
• W4286295684 creator A5059404809 @default.
• W4286295684 creator A5061072132 @default.
• W4286295684 creator A5061348179 @default.
• W4286295684 creator A5068853953 @default.
• W4286295684 creator A5069137747 @default.
• W4286295684 creator A5069613777 @default.
• W4286295684 creator A5072271778 @default.
• W4286295684 creator A5090545021 @default.
• W4286295684 date "2022-06-01" @default.
• W4286295684 modified "2023-10-17" @default.
• W4286295684 title "A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS)." @default.
• W4286295684 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.tps9593" @default.
• W4286295684 hasPublicationYear "2022" @default.
• W4286295684 type Work @default.
• W4286295684 citedByCount "0" @default.
• W4286295684 crossrefType "journal-article" @default.
• W4286295684 hasAuthorship W4286295684A5001015275 @default.
• W4286295684 hasAuthorship W4286295684A5007005578 @default.
• W4286295684 hasAuthorship W4286295684A5012911914 @default.
• W4286295684 hasAuthorship W4286295684A5022491020 @default.
• W4286295684 hasAuthorship W4286295684A5025478490 @default.
• W4286295684 hasAuthorship W4286295684A5026878751 @default.
• W4286295684 hasAuthorship W4286295684A5029783882 @default.
• W4286295684 hasAuthorship W4286295684A5034414974 @default.
• W4286295684 hasAuthorship W4286295684A5037624715 @default.
• W4286295684 hasAuthorship W4286295684A5041474007 @default.
• W4286295684 hasAuthorship W4286295684A5056132643 @default.
• W4286295684 hasAuthorship W4286295684A5058902095 @default.
• W4286295684 hasAuthorship W4286295684A5059404809 @default.
• W4286295684 hasAuthorship W4286295684A5061072132 @default.
• W4286295684 hasAuthorship W4286295684A5061348179 @default.
• W4286295684 hasAuthorship W4286295684A5068853953 @default.
• W4286295684 hasAuthorship W4286295684A5069137747 @default.
• W4286295684 hasAuthorship W4286295684A5069613777 @default.
• W4286295684 hasAuthorship W4286295684A5072271778 @default.
• W4286295684 hasAuthorship W4286295684A5090545021 @default.
• W4286295684 hasConcept C121608353 @default.
• W4286295684 hasConcept C126322002 @default.
• W4286295684 hasConcept C143998085 @default.
• W4286295684 hasConcept C16005928 @default.
• W4286295684 hasConcept C2777701055 @default.
• W4286295684 hasConcept C2780030458 @default.
• W4286295684 hasConcept C2780057760 @default.
• W4286295684 hasConcept C31760486 @default.
• W4286295684 hasConcept C509974204 @default.
• W4286295684 hasConcept C535046627 @default.
• W4286295684 hasConcept C71924100 @default.
• W4286295684 hasConcept C82210918 @default.
• W4286295684 hasConceptScore W4286295684C121608353 @default.
• W4286295684 hasConceptScore W4286295684C126322002 @default.
• W4286295684 hasConceptScore W4286295684C143998085 @default.
• W4286295684 hasConceptScore W4286295684C16005928 @default.
• W4286295684 hasConceptScore W4286295684C2777701055 @default.
• W4286295684 hasConceptScore W4286295684C2780030458 @default.
• W4286295684 hasConceptScore W4286295684C2780057760 @default.
• W4286295684 hasConceptScore W4286295684C31760486 @default.
• W4286295684 hasConceptScore W4286295684C509974204 @default.
• W4286295684 hasConceptScore W4286295684C535046627 @default.
• W4286295684 hasConceptScore W4286295684C71924100 @default.
• W4286295684 hasConceptScore W4286295684C82210918 @default.
• W4286295684 hasIssue "16_suppl" @default.
• W4286295684 hasLocation W42862956841 @default.
• W4286295684 hasOpenAccess W4286295684 @default.
• W4286295684 hasPrimaryLocation W42862956841 @default.
• W4286295684 hasRelatedWork W2155654588 @default.
• W4286295684 hasRelatedWork W2296139876 @default.
• W4286295684 hasRelatedWork W2518309888 @default.
• W4286295684 hasRelatedWork W2811288290 @default.
• W4286295684 hasRelatedWork W2957427793 @default.
• W4286295684 hasRelatedWork W3086685948 @default.
• W4286295684 hasRelatedWork W3185931698 @default.
• W4286295684 hasRelatedWork W3214274450 @default.
• W4286295684 hasRelatedWork W4283386348 @default.
• W4286295684 hasRelatedWork W4286295684 @default.
• W4286295684 hasVolume "40" @default.
• W4286295684 isParatext "false" @default.
• W4286295684 isRetracted "false" @default.
• W4286295684 workType "article" @default.